• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics

    Almac Group Completes $7M R&D Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre

    AARDEX Group Partners with Pill Connect

    Phillips-Medsize and Subcuject Collaborate
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    test company saurabh

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Almac Group

    test company saurabh
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    Contract Pharma’s 20th Anniversary Series: CRO Perspective

    Randy Marchbanks of PPD discusses how CRO operations have evolved to accommodate changing industry needs

    Related CONTENT
    • Legacy Pharma Solutions
    • PCI Pharma Services
    • Catalent Pharma Solutions
    • Mogene
    • Regis Custom Pharma
    Kristin Brooks, Contract Pharma10.28.19
    Unimaginable innovation in drug development has led to more complex and increasingly targeted therapies for smaller patient populations, particularly in the rare and orphan disease space. In clinical research, this translates into challenges, such as logistics and patient recruitment, that require global operations, advanced analytics, data and communications capabilities and scientific expertise.
     
    Contract Research Organizations (CROs) have grown into a global industry these past 20 years, offering services across the drug discovery and development continuum. From their clinical origins, CROs have since added lab services, regulatory consulting, data capture and analytics platforms, as well as scale, all with the goal of helping sponsors to advance their drug development programs, make go/no-go decisions faster, provide critical information and quality data in real-time.
     
    Randy Marchbanks, Senior Vice President, global development operations at PPD, discusses how CRO operations have evolved to accommodate changing industry needs and what we can expect for the future of the industry and outsourcing. –KB
     
    Contract Pharma: What were some of the major pharma/biopharma industry changes in the past 20 years that have significantly impacted contract service providers? 
     
    Randy Marchbanks: Broadly speaking, there have been two major changes in the pharma/biopharma industry over the past 20 years that have changed the landscape for contract service providers.  The first has been the continued consolidation of established, traditional biopharma companies combined with an unprecedented expansion of biotech companies.  With both, cost and time pressures to bring new products to the market has driven the need for biopharma companies to increase productivity via identifying core competencies to internalize while outsourcing other activities. Global service providers have responded by expanding the global scope, scale and expertise of their offerings, allowing biopharma companies to outsource increasingly complex scientific, medical, analytical and clinical services to these providers. 
     
    The second change has been the shift in the portfolio of products under development by biopharma industry from traditional, small molecules targeting common maladies to a complex array of biological assets with specific therapeutic targets or products intended to treat rare diseases.  This shift has resulted in a massive expansion, and in some cases the transfer, of bioanalytical expertise and specialty clinical laboratory testing to service providers. Further, the shift to clinical trials with targeted therapies and for rare diseases has pressured service provider to significantly expand their geographic footprint and patient recruitment expertise to find trial-eligible subjects with specific genetic markers.
     
    CP: What are some changes you anticipate for the future of the industry and outsourcing?
     
    RM: Service providers have experienced some dramatic swings in outsourcing approaches for the biopharma industry over the past two decades from best-in-class outsourcing to multiple providers for specific services to seeking single, global service providers that can provide high quality end-to-end laboratory and clinical trial support.  The outsourcing of either single services or broader support has also been contracted in diverse ways including single study contracts to larger scale outsourcing of an entire function (functional service provider or FSP), dedicated full-time employees for specialized laboratory services or full-service outsourcing (FSO) of a single trial or entire development program.  While major changes across these diverse outsourcing options are not expected, contract service providers should be anticipating the upcoming needs from our biopharma customers.    
     
    CP: How have service offerings and operations for CROs evolved over the years? 
     
    RM: The CRO industry has experienced exponential growth over the past 20 years, evolving from small, often single-region organizations with limited service offerings to multinational business enterprises offering an ever-expanding menu of services.  Almost unthinkable advances in science in technology over this time have enabled this evolution across all of our global services and functions.  One example is our pharmacovigilance team’s development of a real-time communication system with sites globally to address protocol inquiries or patient eligibility questions and development of an advanced case processing system with associated metric generation utilizing artificial intelligence (AI) and machine learning (ML) to increase productivity and reduce cost. Across our global laboratory businesses, implementation of numerous technological enhancements has driven significant global expansion and the movement from repetitive quality control functions to high science in support of the development of new products. 

    On the clinical front, the importance of moving clinical trial sites from agreement to participate to fully activated and eligible to enroll subjects has led to development of a sophisticated global department of professionals with a variety of skill sets (regulatory, legal, financial, etc.), positively impacting overall study timelines. To identify the best sites for clinical trials, the expertise of a separate team focused on patient centricity, engagement with internal and external data sources and strategic site collaborations has also been formed.  Finally, critical clinical trial services that have evolved over the past 20 years include our global clinical supplies team who deal with complex trade compliance and import/export laws and regulations and out global data management organization which handles, processes and cleans electronic trial data from multiple data sources.
     
    CP: What global market changes have had the greatest impact on the industry and CRO services? 
     
    RM: As mentioned earlier, the need to identify increasingly difficult to find subjects for clinical trials influenced the biopharma industry and CROs to expand their geographic interest and footprint to new global markets over the past 20 years.  Coincident with that, government agencies, regulatory bodies and ethics professionals around the world initiated the processes of harmonization, standardization and the governance of clinical trials globally.  This harmonization allowed biopharma companies to design and execute global trials in support of marketing applications in several countries, negating the need for local trials to support marketing of new products.
     
    The clinical research landscape, which had been largely confined to the US and Western Europe, first expanded to Eastern Europe and Latin America and in the late 1990’s and then further expanded into Japan, China and other Asia-Pacific (APAC) countries thereafter. The true globalization of clinical trials facilitated the substantial expansion of CROs into these regions.  In addition to expanding their global footprint, this expansion also afforded the CROs to opportunity to tap into a larger pool of highly qualified resources to support their clinical and laboratory businesses in those regions.
     
    CP: What are some of the major regulatory changes that have impacted the industry in the past 20 years?
     
    RM: In addition to the adoption of ICH E6 Good Clinical Practice (GCP) Guideline in 1996, implementation of Data Privacy standards around the collection, analysis, transfer and archiving of clinical trial data has had the biggest impact on the biopharma and CRO industry.  More recently, the release of ICH E6 R2 has initiated a fundamental shift if the way biopharma companies and CROs actively manage clinical trials – moving from a mindset of retrospectively monitoring clinical trial activities to a more proactive risk identification and risk management approach.  To address the requirement of the new guidance, the industry has developed and implemented sophisticated data analytics systems to monitor key quality indicators (KQIs) in real time to quickly identify and address issues.
     
    Finally, the FDA and other regulatory agencies are increasingly collaborating with the industry to innovate both the clinical trials process as well as the submission of marketing applications. A good example of this is the FDA’s acceptance, and even encouragement, of novel trial designs such as adaptive trials, platform trials and basket trials as well as the utilization of real-world evidence (RWE) to improve the efficiency of the clinical trials process.  Further, there has been a movement toward acceptance of scientifically validated surrogates of response (such as biomarkers) as safety and efficacy endpoints.  Finally, regulatory bodies worldwide are also collaborating with each other to streamline the marketing application and review process.  In fact, in September the FDA, in conjunction with the Australian TGA and Health Canada under an initiative called Project Orbis, announced its first joint approval for oncology drugs granting accelerated approval for novel products targeting an unmet medical need.
     
    In summary, the biopharma and CRO industries have simultaneously evolved – in more ways than we could have predicted –over the past 20 years. If this progress is an indication of what’s to come, we need to collectively fasten our seat belts for the next 20 years!


    Randy Marchbanks, Pharm.D., serves as senior vice president of development operations within PPD’s global clinical development team. In this role, he is responsible for leading the development operations efforts for PPD’s strategic partnership accounts. Leveraging his years of operations and commercial experience, his strong customer knowledge and his positive relationships with colleagues, Dr. Marchbanks provides oversight of all strategic partnership development operations leaders to ensure partnerships progress according to strategic development plans. Since joining PPD in 1993, Dr. Marchbanks has held several management positions in the company’s clinical operations and commercial teams, most recently serving as vice president of commercial development.
    Related Searches
    • china
    • Clinical Trial
    • asia-pacific
    • study
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Mogene Mogene
    Regis Custom Pharma Regis Custom Pharma
    Mikart Mikart's Gus Labella
    Exelead Exelead's Alex Aust
    Alcami Alcami's Brittany Jackway
    Federal Equipment Federal Equipment's Adam Covitt
    Contract Pharma’s 20th Anniversary Series: CDMO Insight Contract Pharma’s 20th Anniversary Series: CDMO Insight
    Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future Keynote: FDA’s Continuous Manufacturing Journey: Past, Present and Future
    Altasciences Altasciences
    Adare Pharma Solutions Adare Pharma Solutions
    Contract Pharma’s 18th Conference & Tabletop Exhibit Was a Another Success! Contract Pharma’s 18th Conference & Tabletop Exhibit Was a Another Success!
    Like It’s 1999 Like It’s 1999

    Related Online Exclusives

    • Biologics, Proteins, Vaccines | Clinical Trials
      Inside a Vaccine Trial

      Inside a Vaccine Trial

      Dr. Murphy of ICON, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
      Kristin Brooks, Managing Editor 02.05.21

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      The Future of Vaccines and Biologics

      The Future of Vaccines and Biologics

      Dr. Linda Marbán of Capricor Therapeutics discusses the advances in responding to infectious diseases.
      Kristin Brooks, Managing Editor, Contract Pharma 02.04.21

    • Clinical Trials | Information Technology
      The State of Clinical Trial Technology

      The State of Clinical Trial Technology

      Blake Adams of Florence discusses key report findings and the clinical trial software used to support Pfizer’s global COVID-19 vaccine study.
      Kristin Brooks, Contract Pharma 01.26.21


    • Analytical Services | Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development | Fill/Finish
      A New Era of Vaccine and Biologic Drug Development

      A New Era of Vaccine and Biologic Drug Development

      As a result of COVID-19, unprecedented investments in vaccines, diagnostics, and treatments have had a tremendous impact on the Biotechnology industry.
      Kristin Brooks, Managing Editor 01.12.21

    • Clinical Trials | Drug Development | Information Technology
      Advancing Digital Endpoints in Clinical Trials

      Advancing Digital Endpoints in Clinical Trials

      An end-to-end approach to managing wearable devices through clinical development.
      Kristin Brooks, Contract Pharma 12.14.20

    • Drug Delivery | Drug Development
      Inhaled Drug Delivery Technology Trends

      Inhaled Drug Delivery Technology Trends

      The success of new inhaled medicines relies on the correct combination of formulation and device technology.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 11.24.20


    • Bioanalytical Services | cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      CDMOs: Keeping up with Science & Technology

      CDMOs: Keeping up with Science & Technology

      Enhancing the development of increasingly advanced and complex drug candidates is needed to drive growth in the industry.
      Kristin Brooks, Contract Pharma 11.12.20

    • Clinical Trials | Drug Development | Preclinical Outsourcing
      Accelerating R&D Trends

      Accelerating R&D Trends

      The pandemic has propelled lingering trends into the forefront and increasingly complex molecules and biologics have drug developers outsourcing more.
      Kristin Brooks, Contract Pharma 10.20.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Contract Pharma 08.25.20


    • Drug Development | Information Technology
      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Trade Secret Litigation: Vulnerabilities Within Pharma Amid Hacking Efforts

      Theft of IP belonging to companies developing biologics and other drugs, including COVID-19 treatments and vaccines, poses a threat to innovation.
      Kristin Brooks, Contract Pharma 08.19.20

    • Drug Development | Industry News
      Top Companies Report: Biogen

      Top Companies Report: Biogen

      Expands pipeline of disease-modifying therapies for Alzheimer’s and Parkinson’s, adds gene therapies focused on AAV treatments, bolsters biosimilars portfolio.
      Kristin Brooks, Contract Pharma 07.10.20

    • Analytical Services | Biologics, Proteins, Vaccines | Drug Development | Drug Discovery | Laboratory Testing
      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      A Shifting Drug Development Landscape Amid COVID-19 Crisis

      Responding to demand for challenging assays and custom solutions required for complex molecules, biologics, vaccines and other innovative therapies.
      Kristin Brooks, Contract Pharma 06.22.20


    • Drug Development | Information Technology
      Advancing AI Initiatives in R&D

      Advancing AI Initiatives in R&D

      Richard Lee of ACD/Labs discusses the possibilities of using AI in R&D, and what this outlook means for IT leaders at pharmaceutical organizations.
      Kristin Brooks, Contract Pharma 06.11.20

    • Clinical Trials
      Impact of COVID-19 on Winning New Business

      Impact of COVID-19 on Winning New Business

      WuXi Clinical’s Vice President of Biometrics, David Ng, talks about the impact of COVID-19 on clinical trials and business relations
      Tim Wright, Editor, Contract Pharma 06.03.20

    • APIs | cGMP Manufacture | Clinical Trials | Supply Chain
      Evaluating Pharma Amid COVID-19

      Evaluating Pharma Amid COVID-19

      Dr. Ural of Ernst & Young LLP discusses market dynamics, enduring therapeutic areas, near term M&A, and how industry can use this time for transformation
      Kristin Brooks, Contract Pharma 05.18.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • ICON Acquires Medpass
    Breaking News
    • Altasciences Contributes to Vibegron Approval
    • Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    • Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    • ACG Launches ACG Laboratories
    • Glatt and Aprecia Enter 3D-Printing Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Launches Sustainability Framework: Futureproof
    ChemQuest Hires Rich Gibson
    New Increase in Kynar Fluoropolymer Capacities at Arkema's Chinese Site
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Terumo to Purchase Predictive Analytics Firm Health Outcomes Sciences
    Abiomed Leader Michael Minogue Named AdvaMed Board Chairman
    TransEnterix Changes Name to Asensus Surgical
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Altasciences Contributes to Vibegron Approval
    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Afro Sheen Launches New Brand Initiatives
    Happi

    Latest Breaking News From Happi

    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    RB Launches Vanish Miracle
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood Technologies debuts new anilox cleaning system
    INX International and VerifyMe sign supply agreement
    Soma partners with DTM Flexo Services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    H&V Announces Price Increase
    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Nexus Spine Implants for Use in Spinal Surgeries Become Available
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login